Scalper1 News
Big pharma Bristol-Myers Squibb (BMY) said Wednesday that it inked a deal worth up to $975 million with Danish biotech Bavarian Nordic for its prostate-cancer vaccine candidate Prostvac, a step forward for a technology that still has yet to prove itself. Bristol agreed to pay $60 million upfront, with the rest of the money dependent on how Prostvac gets through its phase-three trial and the FDA approval process. Bristol said it’s also planning a Scalper1 News
Scalper1 News